




PHARMACEUTICAL 2018

Viking Therapeutics Inc.
Rank 234 of 342





PHARMACEUTICAL 2018

Viking Therapeutics Inc.
Rank 234 of 342

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Viking Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 29% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	21,852
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,657
Liabilities, Non-Current	0
Other Assets	270
Other Compr. Net Income	-13
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,507
Other Revenues	0
Property and Equipment	0
Research and Development	13,741
Selling, General and Administrative Expense	5,329

Output Variable	Value in 1000 USD
Assets	22,121
Liabilities	8,657
Expenses	19,070
Revenues	0
Stockholders Equity	13,465
Net Income	-20,578
Comprehensive Net Income	-20,584
Economic Capital Ratio	17%